Chromatin Immunoprecipitation Analysis of Gene Expression in the Rat Uterus in Vivo: Estrogen-Induced Recruitment of Both Estrogen Receptor {alpha} and Hypoxia-Inducible Factor 1 to the Vascular Endothelial Growth Factor Promoter

Armina A. Kazi, Jenny M. Jones and Robert D. Koos

Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201

Address all correspondence and requests for reprints to: Robert D. Koos, Ph.D., Department of Physiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201-1559. E-mail: rkoos{at}umaryland.edu.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Vascular endothelial growth factor (VEGF) plays a pivotal role in the regulation of microvascular permeability and angiogenesis, processes essential for normal endometrial growth and implantation. Estrogen [17ß-estradiol (E2)], via its receptor (ER{alpha}), rapidly stimulates VEGF expression in the uterus at the transcriptional level. The VEGF gene promoter, however, lacks a consensus estrogen response element (ERE), and attempts to identify the site through which E2 induces VEGF expression have yielded contradictory results. To address this question, we modified the chromatin immunoprecipitation method to identify transcription factors that interact with the VEGF promoter in the rat uterus in response to E2. Chromatin immunoprecipitation showed that both Sp1 and Sp3 were associated with a proximal, GC-rich region of the promoter before E2 treatment. E2 induced an increase in Sp1 binding and the recruitment of ER{alpha}, and the coactivator p300 to this region. The association of ER{alpha} persisted, however, after VEGF mRNA levels had declined again (at 4 h), indicating that other factors might be involved in that expression. Western analysis showed that both the {alpha}- and ß-subunits of the transcription factor hypoxia-inducible factor 1 (HIF-1), which regulates VEGF expression in response to hypoxia and several hormones and growth factors, were present in the uterus. Furthermore, E2 rapidly induced their recruitment to the –944 to –611 bp region of the VEGF promoter, which contains the hypoxia response element to which HIF-1 binds. This binding was transient, matching the pattern of E2-induced VEGF expression. These results indicate that HIF-1 is an important mediator of E2-induced VEGF expression in the uterus. In addition, E2 also induced a later increase in HIF-1{alpha} mRNA and protein expression in the uterus, suggesting that it may be required for longer term effects of E2 on the uterus as well. In contrast to the uterus, HEC1A cells cultured in 95% air-5% CO2 (and therefore 20% O2) contained no HIF-1{alpha}, consistent with the inability of E2 to stimulate the expression of VEGF by these and other cell types in vitro.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
VASCULAR ENDOTHELIAL GROWTH factor (VEGF) plays a central role in the induction of increased microvascular permeability and in angiogenesis (1, 2), processes that are essential for the normal development of the uterine endometrium during the reproductive cycle and for implantation (3, 4). This laboratory and others have shown that estrogen [17ß-estradiol (E2)], the primary stimulus of cyclic endometrial growth, rapidly induces VEGF expression in the uterus in vivo (5, 6). This effect occurs at the transcriptional level and involves E2 receptors (ERs). There are, however, no consensus estrogen response elements (EREs) on the VEGF promoter, and attempts to identify the sites through which ERs act to induce VEGF expression have yielded inconsistent and contradictory results. Hyder and Stancel (7) identified two putative variant EREs located within the rat VEGF 5'- and 3'-untranslated regions (UTRs) based on ERE homology, binding of ERs in gel shift assays, and their ability to mediate E2-induced reporter gene expression in ER-transfected HeLa cells. The artificial nature of this model system, the relatively uncommon location of the two sites, and the fact that the site in the 5'-UTR only mediated increased VEGF expression in the reverse orientation raise questions as to the actual involvement of these sites in E2 regulation of VEGF expression in normal target cells. Furthermore, another group attributed E2 induction of VEGF expression in human endometrial epithelial and adenocarcinoma cells to a completely different variant ERE located approximately 1.5 kb upstream of the transcriptional start site (8). An alternative mechanism of E2-induced gene expression is via ER association with other transcription factors and response elements (9, 10, 11). In two studies, Stoner et al. (12, 13) demonstrated that the effects of E2 on VEGF expression in human cancer cells involved ER{alpha} interactions not with EREs but with Sp1 and Sp3 on a proximal, GC-rich segment (–66 to –47) of the promoter. Interestingly, however, this site mediated E2 suppression of VEGF expression in HEC1A endometrial cancer cells but induction in ZR-75 breast cancer cells. In the latter cells, ER{alpha} and Sp1/3 were already associated with this region before E2 treatment. These results suggest that additional activation events or cellular factors are involved.

VEGF expression is also strongly induced in cells by hypoxia. As we have shown, this occurs via a hypoxia response element on the VEGF promoter, which binds the transcription factor hypoxia-inducible factor 1, or HIF-1 (14). HIF-1 is a heterodimeric protein consisting of a hypoxia-induced {alpha}-subunit and a constitutively expressed ß-subunit, also known as the aryl hydrocarbon receptor nuclear translocator (ARNT) (15). Under normoxic conditions, HIF-1{alpha} is produced but rapidly degraded, resulting in low basal levels in normal tissues (16, 17). Hypoxia inhibits HIF-1{alpha} ubiquitination and degradation, causing its rapid accumulation in cells (18, 19). Interestingly, it has recently been shown that HIF-1{alpha} mediates the induction of VEGF expression by several hormones, growth factors, and cytokines. These include insulin (20), angiotensin II (21), thrombin (22), endothelin-1 (23), IGF-1 (24), prostaglandin E2 (25), epidermal growth factor (26), IL-1 (27), nitric oxide (28), and the catecholestrogen 4-OHE2 (29). There have been, however, no studies linking it to E2-induced VEGF expression.

Recently, a method called chromatin immunoprecipitation (ChIP) was developed to analyze the interaction of transcription factors with target gene promoters in native chromosomal DNA (reviewed in Ref. 30). Performed on cells collected at intervals after experimental treatment, ChIP can reveal the order and timing of transcriptional complex assembly and disassembly. It has been used, for example, to demonstrate dynamic ER{alpha} interaction with coactivator proteins and target gene promoters (31) and with Sp1 (32) in breast cancer cells in vitro. ChIP results are more physiological than those obtained using reporter gene, mobility shift, or DNase footprinting assays because they reflect interactions between endogenous nuclear proteins and chromatin DNA in cells. We hypothesized that ChIP could also be performed on uterine tissue isolated from rats after E2 treatment in vivo. The feasibility of this approach was subsequently demonstrated in studies on liver (33, 34). We adapted ChIP, therefore, to examine the interaction of transcription factors with the VEGF promoter in the uteri of rats after E2 treatment in vivo.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
E2 Stimulates Increased VEGF Expression and Uterine Edema
To correlate VEGF transcription with the induction of uterine edema and binding of transcription factors to the VEGF gene promoter (below), VEGF mRNA levels in uteri were determined by RT-PCR. As expected (5), uterine edema was preceded by increased expression of VEGF mRNA isoforms 120 and 164 (Fig. 1Go). VEGF mRNA levels had declined again to the pretreatment level by 4 h. Uterine wet weight increased by 43% during this period (from 28.2 ± 2.3 g at 0 h to 39.6 ± 3.3 g at 4 h; P < 0.01, n = 9/group). As we have demonstrated previously (3), this edema is dependent on VEGF action.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1. Effect of E2 on VEGF mRNA Expression in Rat Uterus

Immature female rats were treated with either vehicle (0 h) or E2 (0.05 µg/g body weight) for the indicated times. Total RNA was extracted from uteri and VEGF mRNA analyzed using conventional (representative gel, panel A) and real-time (panel B) RT-PCR. The VEGF primers encompass the alternative splice site and generate products for both the VEGF164 and VEGF120 isoforms. Real-time results are expressed as the fold increase in VEGF mRNA levels compared with uteri not exposed to E2 (i.e. 0 h) after normalization to 18S rRNA (means ± SEM, n = 3 uteri per group). a, P < 0.05 vs. 0 h.

 
Validation of the ChIP Method for Use with the Whole Uterus
To identify transcription factors that associate with the VEGF promoter in uterine cells after E2 treatment, we used the ChIP method. Before applying it to uterine samples, however, we first confirmed that we could use the basic methodology to detect E2-induced ER{alpha} association with the promoter of the pS2 gene in MCF-7 cells (31). As shown in Fig. 2Go, an increase in ER{alpha} binding to a region of the pS2 promoter (–436 to +19) that contains a nonconsensus ERE essential for E2 induction was detected. E2 also induced a rapid association of the transcriptional coactivator p300 with the same region. The rapid occupancy of the pS2 promoter by ER{alpha} and p300 after E2 exposure was similar to that reported by Shang et al. (31). When nonimmune serum was substituted for the specific antisera, no PCR products were generated.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2. E2-Induced Recruitment of ER{alpha} and p300 to the pS2 Promoter in MCF-7 Cells

MCF-7 cells were treated with either vehicle or E2 (100 nM) for 30 min. ChIP analysis was done using normal serum (No Ab) or antibodies for ER{alpha} or p300 and PCR primers for the –436 to +19 region of the human pS2 promoter, which contains a variant (v) ERE required for E2 induction. A, The location of the variant ERE. B, Representative ChIP PCR gels (n = 3 replicate wells). Input indicates samples before immunoprecipitation. Ab, Antibody.

 
We next determined whether ChIP, with appropriate modifications, could be used to identify transcription factors that bind to E2-responsive gene promoters in the rat uterus in vivo. To do this, we examined the promoter of the creatine kinase B (CKB) gene. In the rat uterus, CKB mRNA expression increases 7- to 10-fold within 1–3 h after E2 treatment (35). This induction is known to involve recruitment of ER{alpha} and Sp1 to a region of the CKB promoter that contains a nonconsensus ERE flanked by two Sp1 sites (32). Using chromatin isolated from homogenates of whole uteri fixed immediately after removal from rats at intervals after treatment with E2, we performed ChIP assays using antibodies to rat ER{alpha} or Sp1 and PCR primers encompassing this region of the rat CKB promoter (–678 to –319). ChIP showed that the association of both Sp1 and ER{alpha} with this region increases within 1 h after E2 treatment (Fig. 3Go). This agrees with results obtained using cultured MCF-7 cells (32) and confirmed that ChIP can be used to examine the association of transcription factors with gene promoters in the rat uterus after E2 treatment in vivo.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3. E2-Induced Recruitment of Sp1 and ER{alpha} to the CKB Promoter in the Rat Uterus

Immature female rats were treated with either vehicle (0 h) or E2 (0.05 µg /g body weight) for the indicated times (n = 4 uteri per group). Uteri were isolated and processed for ChIP analysis. Immunoprecipitations were carried out using normal serum or antibodies for Sp1 or ER{alpha}. Primers for the –678 to –319 region of the rat CKB gene (panel A) were used for PCR. B, Representative ChIP PCR gels. Ab, Antibody; vERE, variant ERE.

 
E2-Induced Recruitment of Sp1, Sp3, ER{alpha}, and p300 to the Rat VEGF Promoter
As discussed previously, a number of in vitro studies have shown that a GC-rich, Sp1-binding region on the proximal VEGF promoter plays an important role in both basal VEGF expression and its induction by a number of factors (36, 37, 38, 39, 40, 41). It was recently shown that both E2-induced inhibition of VEGF gene expression in HEC1A endometrial cancer cells (12) and stimulation in ZR-75 breast cancer cells (13) also involves ER{alpha}/Sp1/Sp3 binding to this region. We initially determined, therefore, whether a similar interaction was also involved in E2-induced VEGF expression in the rat uterus. As shown in Fig. 4Go, both Sp1 and Sp3 were already associated with the –173 to +114 region of the VEGF promoter at 0 h. Constitutive binding of these two factors to the same region of the VEGF promoter has been described previously (13, 36). Treatment with E2 significantly increased the binding of Sp1 by 1 h (+3.4-fold; P < 0.05); Sp3 association also increased approximately 2-fold, but the change was not statistically significant. To demonstrate the specificity of the ChIP results, we also performed PCR using primers to a portion of the 3'-UTR of the VEGF gene (660–922, as numbered in Ref. 42). No Sp1 interaction with this region was detected (data not shown).



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4. E2-Induced Recruitment of Sp1 and Sp3 to the VEGF Promoter in the Rat Uterus

Rats were treated as described for Fig. 3Go. Immunoprecipitations were carried out using normal serum or antibodies for Sp1 or Sp3. Primers for the –173 to +114 region of the rat VEGF promoter (panel A), which contains at least three Sp1 sites (and an AP-2 site), were used for PCR. B, Representative ChIP PCR gels. C, ChIP real-time PCR results expressed as the fold increase compared with 0 h (means ± SEM, n = 4 uteri per group). a, P < 0.05 vs. 0 h and 4 h. Ab, Antibody; AP-2, activator protein 2.

 
Little or no ER{alpha} was associated with this same region at time zero, but E2 induced a marked recruitment of both ER{alpha} (+3.8-fold; P < 0.01) and p300 (>2-fold; P < 0.05) to this region within 1 h (Fig. 5Go). By 4 h, by which time VEGF mRNA levels had returned to pretreatment levels (Fig. 1Go), ER{alpha} and p300 occupancy of the promoter was still elevated, whereas Sp1 binding had returned to the pretreatment level (Fig. 4Go).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 5. E2-Induced Recruitment of ER{alpha} and p300 to the VEGF Promoter in the Rat Uterus

Immunoprecipitations were carried out using normal serum or antibodies for either ER{alpha} or p300. Primers for the –173 to +114 region of the rat VEGF gene, as shown in Fig. 4Go, were used for PCR. A, Representative ChIP PCR gels. B, ChIP real-time PCR results expressed as the fold increase compared with 0 h (means ± SEM, n = 4 uteri per group). a and b, P < 0.01 and P < 0.05, respectively, vs. 0 h. Ab, Antibody.

 
We also examined the association of ER{alpha} with three 5'-upstream regions of the VEGF promoter (–124 to –403, –384 to –661, and –611 to –944). Although there was an enhanced yield of PCR product for the two immediate upstream regions after E2 treatment, the signal was weaker and less consistent than that obtained for the GC-rich region (data not shown). Because sonication of chromatin yields fragments of varying size, these signals most likely derive from larger chromatin fragments containing both the targeted region and the GC-rich region. No association of ER{alpha} with the most 5'-region was detected (Fig. 6Go). The absence of equal or stronger association with the first two upstream regions, and the absence of any signal from the most distant upstream region, indicates that the major site of ER{alpha} association is with the proximal GC-rich, Sp1/Sp3-binding region of the VEGF promoter, as previously indicated in studies using human cancer cells (12, 13), rather than with variant EREs (7, 8).



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6. E2-Induced Recruitment of HIF-1{alpha}, HIF-1ß, and p300 to the VEGF Promoter in the Rat Uterus

Immunoprecipitations were carried out using normal serum or antibodies for HIF-1{alpha}, HIF-1ß, ER{alpha}, and p300. Primers for –944 to –611 region of the rat VEGF promoter (A), which contains the HRE to which HIF-1 binds (as well as an AP1 and an Sp1 site), were used for PCR. B, Representative ChIP gels. C, ChIP real-time PCR results expressed as the fold increase compared with 0 h (means ± SEM, n = 4 uteri for HIF-1{alpha} and p300; mean and range, n = 2 uteri for HIF-1ß). a, P < 0.01 vs. 0 h; b, P < 0,05 vs. 4 h; c, P < 0.05 vs. 0 h. Ab, Antibody; AP-1, activator protein 1.

 
E2-Induced Recruitment of HIF-1{alpha} and HIF-1ß to the Rat VEGF Promoter
Although no association of ER{alpha} with the –944 to –611 region was observed, this region does contain the HIF-1 binding site essential for VEGF-induction by hypoxia (14). As discussed previously, HIF-1 has also been implicated in the induction of VEGF expression by several hormones and growth factors. Therefore, the recruitment of both HIF-1{alpha} and HIF-1ß to this region of the promoter in the uterus after E2 treatment was examined. Figure 6Go shows that at 0 h, little or no HIF-1{alpha} or HIF-1ß was present on this promoter region, but, after E2 treatment, both these components of the heterodimeric transcription factor were rapidly recruited to it (3.4-fold and 4.4-fold at 1 h vs. 0 h, respectively). This pattern of binding closely matched the pattern of VEGF mRNA expression (Fig. 1Go). Both HIF-1 components had dissociated by 4 h, again matching the pattern of VEGF mRNA expression. Like ER{alpha}, HIF-1 regulation of gene transcription requires interaction with p300 (43, 44). Consistent with this, a matching increase in the association of p300 with this region was detected (Fig. 6Go). This correlation between HIF-1 and p300 binding to the VEGF promoter and E2-induced VEGF mRNA expression strongly suggests that HIF-1 recruitment plays an integral role in this event.

E2 Induction of HIF-1{alpha} Expression in the Uterus
HIF-1{alpha} levels increase sharply during hypoxia, leading to HIF-1-mediated expression of a wide range of genes critical for short-term adaptation to and long-term alleviation of hypoxia (45). This occurs mainly at the posttranslational level via stabilization of HIF-1{alpha} protein. To determine whether the rapid E2-induced increase in HIF-1 association with the VEGF promoter was due in any part to such an increase in the level of HIF-1{alpha}, we assessed the effects of E2 on HIF-1{alpha} and HIF-1ß protein expression by Western blot analysis. As shown in Fig. 7Go, both HIF-1{alpha} and HIF-1ß were present in the rat uterus before E2 treatment. In both cases, the sizes of the bands were similar to the published sizes for the two proteins (~120 and ~95 kDa, respectively). Similar results were obtained for HIF-1{alpha} using two different antibodies, further confirming the identity of the band, whereas the HIF-1ß band matched exactly that obtained with a HIF-1ß standard provided by the antibody supplier (see Materials and Methods). There was no significant change in the level of HIF-1{alpha} at 0.5 or 1 h. Thus, the HIF-1{alpha} associated with the VEGF promoter 1 h after E2 treatment appears to represent recruitment of existing HIF-1{alpha} protein. The level of HIF-1{alpha} was significantly higher, however, at 2 h (3-fold) and 4 h (4-fold). This suggests that higher levels of HIF-1{alpha} are required for later as well as early effects of E2 on gene expression. Similar to other tissues (16), HIF-1ß was abundant in the uterus and was unchanged after E2 treatment (Fig. 7Go), as is the case with hypoxia.



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 7. Effect of E2 on HIF-1{alpha} and HIF-1ß Protein Expression in the Rat Uterus

Immature female rats were treated as described previously. Western blot analysis was performed using antibodies for HIF-1{alpha} (in this case the Novus antibody) or HIF-1ß. Protein (20 µg) was loaded in each well for HIF-1{alpha} and 40 µg for HIF-1ß. A, Representative blots. B, Relative amount of HIF-1{alpha} quantified by densitometric scanning and normalized to the HIF-1ß signal, which was unchanged after treatment with E2 (means ± SEM, n = 3 uteri per group). a, P < 0.05 vs. 0 h.

 
To determine whether the E2-induced increase in HIF-1{alpha} protein was due to increased protein stability or an increase in mRNA expression, HIF-1{alpha} mRNA was also measured by real-time RT-PCR. As shown in Fig. 8Go, the delayed increase in HIF-1{alpha} protein was matched by an increase in HIF-1{alpha} mRNA (~2.5-fold at 2 h and 3.1-fold at 4 h; P < 0.01 in both cases). This indicates that E2 induction of HIF-1{alpha} expression, unlike the effect of hypoxia and most other stimuli, is at least in part at the level of transcription. Such an effect on HIF-1{alpha} transcription is rare but has been observed to occur in smooth muscle cells in response to angiotensin II (46).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8. Effect of E2 on HIF-1{alpha} mRNA Expression in the Rat Uterus

Immature female rats were treated as described previously and total RNA was extracted and HIF-1{alpha} mRNA analyzed using conventional (representative gel, panel A) and real-time (panel B) RT-PCR. Real-time results are expressed as the fold increase in HIF-1{alpha} mRNA levels over cells not exposed to E2 (i.e. 0 h) after normalization to 18S rRNA (means ± SEM, n = 3 uteri per group. a and b, P < 0.05 and P < 0.01, respectively, vs. 0 h.

 
Absence of HIF-1{alpha} in Cultured E2-Target Cells Correlates with the Inability of E2 to Stimulate VEGF Expression in Vitro
There is, at this time, no proven method for the specific inhibition of HIF-1{alpha} production or activity in vivo. Exposure to high, nonphysiological O2 levels, however, effectively induces destruction of cellular HIF-1{alpha} (16, 47, 48). Culturing cells under standard conditions (i.e. in 95% air-5% CO2, and thus 20% O2), therefore, would be predicted to suppress HIF-1{alpha} to very low or undetectable levels. Thus, we hypothesized that there would be no HIF-1{alpha} in the endometrial or breast cancer cells commonly used for the study of E2 action, which could explain the weak effect of E2 on the expression of VEGF by such cells, at least compared with the uterus in vivo (12, 49, 50, 51, 52). We have found, for example, that E2 has little or no stimulatory effect on the expression of VEGF by HEC1A endometrial carcinoma cells under standard culture conditions (data not shown). To demonstrate that this correlates with a lack of HIF-1{alpha}, we measured HIF-1{alpha} protein levels in HEC1A cells cultured in 95% air-5% CO2. As shown in Fig. 9Go, these cells contain no detectable HIF-1{alpha}. To demonstrate that the cells could express HIF-1{alpha} if the O2 level was reduced, they were also cultured under low O2 (1–2%). This caused a large increase in HIF-1{alpha} protein (Fig. 9Go). This was matched by a 3-fold increase in VEGF mRNA levels at the same time point (n = 5 independent experiments; P < 0.01), demonstrating that the lack of stimulation of VEGF expression by E2 is not due to a general inability of the cells to increase VEGF expression. Taken together, these results are in keeping with the hypothesis that HIF-1{alpha} is required for strong E2 stimulation of VEGF expression.



View larger version (53K):
[in this window]
[in a new window]
 
Fig. 9. HIF-1{alpha} Protein Is Abundant in Cells Cultured in 1–2% But Not 20% Oxygen

Western blot showing HIF-1{alpha} protein levels in HEC1A cells cultured for 18 h in either 20% (left three lanes) or 1–2% (right three lanes) oxygen. Before transfer, cell lysates were electrophoresed under nonreducing conditions on a 7.5% polyacrylamide gel. Under these conditions, the HIF-1{alpha} monomer appears as a diffuse band between 110–130 kDa. The upper band presumably represents the HIF-1{alpha}/HIF-1ß heterodimer.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
These are, to the best of our knowledge, the first analyses ever done on transcription factor interactions with an endogenous E2-responsive gene in a normal target tissue in vivo. The successful application of ChIP in vivo opens the way to physiological studies of the regulation of gene expression by hormones, growth factors, and other stimuli in normal tissues, as opposed to cancer cell lines, and without the use of artificial promoter-reporter gene constructs or receptor expression plasmids.

The major finding of this study is that E2 rapidly causes recruitment of both ER{alpha} and HIF-1 to the VEGF gene promoter in cells of the uterus. The likely site of this event is the endometrial luminal epithelial cell layer, the site of E2-induced VEGF expression (see below). This is the first time that HIF-1 has been linked to E2-induced gene expression. HIF-1 association with the promoter is transient, closely matching the pattern of VEGF expression, whereas that of ER{alpha} persists after VEGF mRNA levels decline. This correlation between HIF-1 binding and transcription indicates that HIF-1 plays a central role in E2 regulation of VEGF expression. The two transcription factors bind at widely spaced sites: HIF-1 to the upstream region containing the hypoxia response element, as it does in response to hypoxia, and ER{alpha} to the proximal GC-rich region that contains several Sp protein binding sites. We found that both Sp1 and Sp3 were associated with the latter region before treatment, and the binding of Sp1 increased further after the addition of E2. These results agree with those of Stoner et al. (12, 13) that ER{alpha} interacts with the VEGF promoter primarily via binding to Sp proteins rather than to variant EREs (7, 8). The role of Sp proteins is not specific, however, to the effect of E2 on VEGF. The proximal Sp protein-binding region has been shown previously to be essential for basal VEGF gene expression (36, 37, 41) and induction by various growth factors (36, 53). It is also not specific to VEGF, because the expression of a number of other genes involves ER{alpha}/Sp1 binding to similar GC motifs (54, 55). Our results suggest that the additional recruitment of HIF-1{alpha} is necessary for the rapid E2-induced increase in the transcription of the VEGF gene in the endometrium. The demonstration of a subsequent increase in HIF-1{alpha} expression raises the distinct possibility that HIF-1 also plays an important role in later effects of E2 on the uterus. HIF-1 has been linked to the regulation of more than 50 genes involved in energy metabolism, cell proliferation/survival, cell migration, and other processes (15). Many of these same genes are expressed cyclically in the uterus, and several are induced by E2. These include adrenomedullin (56), endothelin-1 (57), erythropoietin (58), IGF-binding proteins (59), and inducible nitric oxide synthase (iNOS) (60). We predict that HIF-1 will be found to be involved in E2 induction of some of these genes as well.

HIF-1 involvement in E2-induced VEGF expression is consistent with several recent studies showing that it also mediates the stimulation of VEGF expression by a number of other hormones, growth factors, and cytokines in various cell types under nonhypoxic conditions (20, 21, 22, 23, 24, 25, 26, 27, 28, 29). These factors appear to act through kinase pathways to increase HIF-1{alpha} protein levels and/or transcriptional activity. Activation leads to translocation to the nucleus, dimerization with HIF-1ß, and recruitment of coactivators, such as p300 (61). Our results indicate that the latter three of these events are triggered by E2. Activation of HIF-1{alpha} is most frequently associated with phosphatidylinositol 3-kinase (PI3K) and MAPK activity (45, 61), both of which can be rapidly activated by E2 (62, 63, 64, 65). Whether this depends on changes in the phosphorylation of HIF-1 or that of associated transcription factors or coactivators is unclear at this time. In preliminary studies, we have not been able to detect a change in the overall phosphorylation state of HIF-1{alpha} after E2 treatment. Activation of HIF-1{alpha} could involve phosphorylation at one or more sites and dephosphorylation elsewhere, as has been shown for other transcription factors. Unfortunately, antibodies to specific phosphorylated forms of HIF-1{alpha} are not yet available. Much more work is needed in this area. Regardless, the rapidity of HIF-1 recruitment and the known role of kinases in its activation raise the possibility that these events could be initiated by membrane ERs (66), which have now been linked to activation of both the MAPK and PI3K pathways (Refs. 67 and 68 and Fig. 10Go). PI3K and/or MAPKs have been shown recently to play a role in hepatocyte growth factor-induced VEGF expression through phosphorylation of constitutively bound Sp1 (53), and other recent studies have also linked phosphorylation of Sp1 by MAPK to VEGF expression (69, 70). Thus, the same kinase pathways might simultaneously activate both HIF-1 and Sp1.



View larger version (64K):
[in this window]
[in a new window]
 
Fig. 10. Model Illustrating Possible Mechanisms for Recruitment of both ER{alpha} and HIF-1 to the VEGF Promoter after E2 Treatment

ChIP results indicate that E2 simultaneously induces the recruitment of both HIF-1 ({alpha} and ß) to the upstream HRE and Sp1 and ER{alpha} to the proximal GC-rich region of the VEGF promoter, probably via interaction with Sp proteins; p300 binds to both transcription factor complexes, a further indication of their transcriptional activation. Because the activation of HIF-1{alpha} by other factors has been linked to the activity of both MAPKs and PI3K, one possible mechanism for its recruitment could be through activation of a membrane form of the ER (here designated ERm). Such receptors have been linked to activation of the same kinases (67 68 ). Such a pathway might also mediate the activation and recruitment of Sp1 to the proximal region.

 
Although E2 rapidly stimulates kinase pathways, it cannot be ruled out that it activates HIF-1{alpha} in part because it causes hypoxia in uterine cells. E2 strongly stimulates endometrial RNA and protein synthesis, glucose oxidation, DNA replication, and other biosynthetic processes (71). The increase in oxygen consumption necessary for this increase in metabolism might, in the short term, exceed the rate of oxygen delivery. On the other hand, E2 also stimulates uterine blood flow, probably via the synthesis of the vasodilator NO, thereby supplying additional oxygen. As mentioned previously, HIF-1 has been linked to iNOS gene expression (15), and E2 induces iNOS in the uterus (60). It is possible that hypoxia and E2 could act synergistically to induce maximal VEGF expression, as is the case for hypoxia and TGF-ß in cultured cells (47).

Because these were in vivo studies, to directly demonstrate that the recruitment of HIF-1 is an absolute requirement for E2 induction of VEGF expression, by somehow blocking its synthesis or action in the uterus, is not possible at this time. In effect, however, this experiment has been performed many times on a variety of E2-responsive cells in vitro. Culturing cells under standard conditions (i.e. in 95% air-5% CO2) exposes them to 20% oxygen, a supraphysiological concentration that suppresses HIF-1{alpha} in cells to undetectable levels (Ref. 48 and Fig. 9Go). If HIF-1 plays an essential role in E2-induced VEGF expression, therefore, E2 should have little or no effect on cells in vitro, which is in fact the case. Most such studies either report no significant effect (49, 50, 51), small (<2-fold) stimulation (52), or inhibition (12) of VEGF expression by E2. We have likewise observed no response from HEC1A endometrial carcinoma cells and only relatively weak or delayed effects in MCF-7 and ZR-75 breast cancer cells (Ref. 72 and our unpublished work). All of the cell types used in these studies possess E2 receptors and exhibit other responses to E2. Studies using cells transfected with VEGF promoter-reporter gene constructs yield similar results, namely modest (8) or no induction by E2 (73). The weak in vitro response to E2 clearly contrasts with the rapid, robust stimulation in the uterus in vivo (Fig. 1Go and Refs. 5 and 6) and with the strong induction by hypoxia in vitro. Only a few studies have reported relatively strong inductions in vitro, in one case with MCF-7 cells (74) and in another with ZR-75 cells (13). As stated previously, we have not been able to duplicate the results of either study with the same cell types in our laboratory. The difference could be due to variations between cell lines, but an alternative explanation is that differences in culture conditions may sometimes lead to the maintenance of an adequate HIF-1{alpha} concentration to mediate E2 induction. This could be caused by inadvertent exposure of cells to lower oxygen levels (e.g. as a result of using culture vessels that retard gas exchange or a large number of culture vessels per incubator) or supplementation with growth factors that stimulate HIF-1 production (24, 75). In one case where stronger stimulation was observed (76), the only time point examined was 24 h after treatment. We have found that the small induction of VEGF in MCF-7 cells by E2 is delayed (72). Such delayed effects could occur via a completely different mechanism than that operating in vivo. Studies are currently underway in our laboratory to define the culture conditions that would maintain a physiological HIF-1 level in cultured cells (i.e. a level that would be sufficient to support E2-induced VEGF expression without being stimulatory itself).

It is unknown at this time whether HIF-1 and the ER{alpha}/Sp1/Sp3 complex, which bind to widely spaced sites on the VEGF promoter, might still interact in some way, perhaps through a looping mechanism. There is evidence that HIF-1{alpha} may bind to the glucocorticoid receptor (77) and HIF-1ß to HNF-4 (78), both members of the nuclear receptor family like ER{alpha}. HIF-1 can also associate with Sp1 (79, 80). Interestingly, HIF-1ß physically associates with ER{alpha} in cells cotransfected with expression plasmids for both genes and acts as a coactivator of E2-induced reporter gene expression (81). Furthermore, ChIP analysis showed that treatment of T47D cells with E2 caused recruitment of both endogenous ER{alpha} and HIF-1ß to the pS2 promoter. Studies of the possible direct interaction of HIF-1{alpha} and/or -1ß with Sp1 or ER{alpha} on the VEGF promoter are now underway in our laboratory. HIF-1{alpha} and/or -1ß can also directly interact with other transcription factors, including cAMP response element-binding protein/activating transcription factor 1, activator protein 1 (AP-1), activator protein 2 (AP-2), and Smad proteins, all of which have been implicated in the regulation of VEGF expression by other stimuli (44, 47, 48, 82, 83). Our studies do not rule out the involvement of additional transcription factors in the effects of E2 on VEGF expression in the uterus, and different combinations of factors may well be involved in specific cells and under different physiological conditions.

Studies in three different rodent species have shown that the site of increased VEGF expression in the uterus in response to E2 is the luminal epithelium (84, 85, 86). In rats, VEGF expression increases in epithelial cells approximately 15-fold during the proestrus estrogen surge (85), and in no other compartment. Similarly, we have measured a 16-fold increase in VEGF mRNA levels in epithelial cells scraped from the endometrium of immature rats at 2 h after E2 treatment, and a much smaller increase in the residual tissue, which is likely attributable to epithelial cell contamination of that fraction because it is impossible to completely remove all epithelial cells by mechanical means (our unpublished data). All three of the aforementioned studies showed little or no VEGF expression in stromal tissue until after progesterone exposure, and no significant VEGF expression in myometrium at all. The epithelial layer is also the site of sharply increased HIF-1{alpha} expression in mice after estrogen exposure (87). Because it is well known that epithelial cells express ERs, and Sp proteins and p300 are ubiquitous, all of the components identified as associating with the VEGF promoter in the uterus after E treatment are present in the epithelial cells. Thus, although the whole uterus was the starting material for these studies, it is highly likely that the events described occurred in the epithelial cell compartment. The decision to use the whole uterus was based on the fact that the ChIP method is only valid if fixation is done rapidly and before there is any significant perturbation of the cells or tissue, e.g. during manipulation to separate cell compartments, which would likely lead to rapid changes in the association of transcription factors with target gene promoters. In retrospect, this approach was especially important with regard to HIF-1{alpha}, because any attempt to isolate subpopulations of endometrial cells would have exposed them to atmospheric oxygen, which causes rapid degradation of this transcription factor (Refs. 16 and 48 and Fig. 9Go). In studies underway in our laboratory, we have observed sharp reductions in HIF-1{alpha} levels in cancer cells cultured under hypoxic conditions after exposure to room air for periods of less than 1 min. Additional evidence that the use of the whole uterus yields results accurately reflecting changes in distinct cell populations is the fact that the our results for ER{alpha} and Sp1 on both the VEGF and CKB promoters are consistent with those obtained previously using human cancer cell lines (13, 32).

In addition to rapidly causing existent HIF-1{alpha} recruitment to the VEGF promoter, E2 also induces HIF-1{alpha} mRNA and protein expression in the uterus. The stimulation of HIF-1{alpha} mRNA levels is rare but not unprecedented (46). It also agrees with the observation of Daikoku et al. (87), who reported a 3.5-fold increase in HIF-1{alpha} transcripts by 6 h and a peak at 12 h after E2 treatment in the ovariectomized mouse uterus. HIF-1 protein levels, however, were not examined in that study. The apparent lack of correlation between increases in HIF-1{alpha} and VEGF mRNAs led those authors to conclude that HIF-1 is not involved in the induction of VEGF by E2. Our ChIP results refute that. Only one other paper has ever examined HIF-1 expression in the uterus (88). In that study on human tissue, only weak, intermittent HIF-1{alpha} and -1ß immunohistochemical staining was seen, and no clear cyclic pattern of expression was apparent. This probably reflects the high variability commonly encountered in immunohistochemical studies of human endometrial samples.

In summary, this study implicates HIF-1in the E2-induced expression of VEGF, a factor essential for normal uterine growth and implantation (3, 4), for the first time. Furthermore, a wide range of uterine diseases and disorders, such as endometriosis, leiomyoma, dysmenorrhea, and endometrial cancer, have been linked to increased VEGF expression (4). HIF-1 is already considered a likely target for the treatment of solid tumors (15), and inhibiting HIF-1 action could be an alternative approach for the treatment of E2-dependent diseases of the uterus, breast, and other E2 target tissues. Combinatorial treatments that target both ERs (or E2 production) and HIF-1 might be especially effective for the treatment of E2-dependent cancers.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Animals and Cells
Animal studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council) and approved by the Institutional Animal Care and use Committee of the University of Maryland School of Medicine. Immature (22 d old), female Sprague Dawley rats (Charles River Laboratories, Inc., Wilmington, MA) were injected sc with 0.2 ml ethanol/PBS vehicle (1:500; controls) or E2, 0.05 µg/g body weight in 0.2 ml vehicle. Animals treated with E2 were killed 0.5, 1, 2, and 4 h later by cervical dislocation. The reproductive tract was exposed though a midline incision, and the uterus and ovaries were excised together and placed on a moistened piece of paper towel on top of a frozen gel pack. The ovaries and oviducts, fat, and mesometrial membranes were quickly trimmed away. Uteri collected from vehicle-treated control animals and the 4 h E2-treated animals were also quickly weighed. Uterine tissue was either stored in RNAlater (QIAGEN, Valencia, CA) for RNA extraction (one half of one horn), flash frozen in liquid nitrogen for protein extraction and Western analysis (one half of one horn), or fixed for ChIP analysis (one horn). The latter was done by cutting open the horn longitudinally using fine scissors, immersing it in 10 ml of 2% formaldehyde in DMEM-F12 medium in a 15-ml polypropylene tube, and rocking for 15 min at room temperature. Fixation was stopped by adding 1.5 ml of 1 M glycine and rocking for an additional 5 min.

The ChIP methodology (below) was first optimized and validated using MCF-7 cells, which were provided by Dr. Angela Brodie (Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine). They were maintained and passaged (1:10) in improved MEM (Biosource International, Camarillo, CA) supplemented with 5% fetal bovine serum (HyClone Laboratories, Inc., Logan, UT) and penicillin-streptomycin (100 U-100 µg/ml; Invitrogen, Carlsbad, CA). They were then plated (4 x 106 cells per 150-mm dish) in improved MEM without phenol red (Biosource International) supplemented with 10% charcoal/dextran-treated fetal bovine serum (HyClone), 2 mM glutamine, and penicillin-streptomycin (as above). After 3 d, they were treated with E2 (100 nM) or vehicle. For ChIP, they were fixed in 1% formaldehyde as described by Shang et al. (31).

HEC1A human endometrial carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA) and grown in DMEM/F-12 medium (CellGro; Mediatech, Herndon, VA) supplemented with 5% fetal bovine serum (HyClone), and penicillin-streptomycin (as above). For experiments, cells were plated in phenol red-free DMEM/F-12 medium with 5% charcoal-stripped fetal bovine serum (HyClone). The serum concentration was reduced to 0.5% 48 h before treatment of cells. Hypoxia was induced in an atmosphere of 5% air, 5% CO2, and 90% N2 in a tri-gas cell culture incubator (Precision Three Gas Incubator; GCA Corp., Chicago, IL), resulting in an oxygen concentration of approximately 1%.

RNA Extraction and Reverse Transcription (RT)
RNA was extracted and purified using the RNeasy Mini Kit (QIAGEN). Uterine tissue was homogenized in buffer RLT (QIAGEN) using a Mini Beadbeater and 1.0-mm zirconia/silica beads (BioSpec Products, Bartlesville, OK). The beads were removed, and the samples were further homogenized/sheared by centrifugation through QIAshredder spin columns (QIAGEN). Total RNA concentration and purity were determined from 260 nm and 280 nm absorbances. RNA was diluted with water to 0.08 µg/µl and reverse transcribed. The RT reaction mixture consisted of 6 µl diluted RNA (0.48 µg), 4 µl 5x Reverse Transcriptase buffer, 4 µl deoxynucleotide triphosphate mix (2.5 mM each of deoxy-ATP, deoxy-CTP, deoxy-GTP, deoxy-TTP), 2 µl 0.1 M dithiothreitol, 2 µl of 1 mg/ml BSA, 1 µl of 0.5 µg/µl random primers, and 1 µl (200 U) of Moloney murine leukemia virus reverse transcriptase (all from Invitrogen, San Diego, CA). The mixture was incubated for 1 h at 37 C.

PCR
Analysis of VEGF and HIF-1{alpha} mRNA expression was done by both conventional and real-time PCR. For conventional PCR, each 30-µl reaction consisted of 3 µl RT, 3 µl 10x buffer, 2.4 µl deoxynucleotide triphosphate mix (as for RT, above), 3 µl 5 µM primer mix, 0.15 µl Taq DNA polymerase (QIAGEN), and 18.45 µl molecular grade water. The optimal number of PCR cycles (the number of cycles yielding detectable product but still within the linear range of amplification) was first determined for each target mRNA (26 cycles for VEGF and 20 cycles for HIF-1{alpha}). Total RNA was diluted 1:1000 before amplification of 18S ribosomal RNA (rRNA) for 16 cycles. An annealing temperature of 60 C was used in all cases. The following primers were used for both conventional and real-time PCR analysis:

rat VEGF +12 to +644: forward 5'-GCTCTCTTGGGTGCACTGGA-3' and reverse 5'-CACCGCCTTGGCTTGTCACA-3' (GenBank accession no. NM031836)

rat HIF-1{alpha} +681 to +890: forward 5'-TGCTTGGTGCTGATTTGTGA-3' and reverse 5'-GGTCAGATGATCAGAGTCCA-3' (GenBank accession nos. AF057308 and NM024359)

human 18S rRNA +364 to +647: forward 5'-CAACTTTCGATGGTAGTCGC-3' and reverse 5'-CGCTATTGGAGCTGGAATTAC-3' (GenBank accession nos. X01117 and h01593)

Both the VEGF and HIF-1{alpha} primer pairs spanned intron-exon borders. PCR products were visualized on 8% polyacrylamide gels, and the relative yield of product per sample was determined by densitometry using a GeneWizard capture and analysis system (Syngene, Cambridge, UK).

Real-time PCR analysis was done using a DNA Opticon system (MJ Research, Boston, MA). Each 30-µl reaction mixture included 3 µl cDNA, 15 µl DyNAmo SYBR green qPCR mix (MJ Research), 1.2 µl primer mix (5 µM each primer), and 10.8 µl molecular grade water. Each sample was assayed in duplicate. A standards curve was generated by serially diluting uterine cDNA. The yield of product for each unknown sample was calculated by applying its threshold cycle, or C(T), value (the cycle at which the sample’s fluorescence trace exceeds background noise and begins to increase linearly) to the standard curve using the Opticon Monitor analysis software (version 1.01, MJ Research). Values were normalized to corresponding 18S rRNA values and expressed as the fold increase relative to 0 h.

In Vivo ChIP
Uterine horns were placed in 1 ml cold Dulbecco’s PBS containing protease inhibitors (Complete Mini EDTA-free Protease Inhibitor Cocktail, 1 tablet/10 ml; no. 1 836 170; Roche Applied Science, Indianapolis, IN) and phosphatase inhibitors (cocktails I and II, 1:100 each; Sigma Chemical Co., St. Louis, MO) briefly before homogenizing in radioimmunoprecipitation buffer [50 mM Tris-HCl (pH 7.4); 1% Nonidet P-40; 0.25% deoxycholic acid; 1 mM EDTA; and protease and phosphatase inhibitors, as described above]. Homogenates were centrifuged at 12,000 rpm for 5 min at 4 C, and the supernatants were removed and discarded. At this point, the ChIP protocol described by Shang et al. (31) was followed with minor modifications. Briefly, pellets were resuspended in 600 µl lysis buffer [50 mM Tris-HCl (pH 8.1); 5 mM EDTA; 1% sodium dodecyl sulfate; and protease inhibitors (as above)] and incubated on ice for 15 min. Samples were sonicated on ice for 10 x 10 sec cycles, with 20-sec pauses between each cycle, using a Microson Ultrasonic Cell Disruptor (Misonix, Farmingdale, NY) at power level 2.5. Sonicated samples were then divided into 100-µl aliquots and stored at –80 C.

Sonicated sample aliquots were thawed on ice and diluted 1:1000 with dilution buffer [20 mM Tris-HCl (pH. 8.1), 150 mM NaCl, 2 mM EDTA, 1% triton X-100, and protease inhibitors (as above)] before being immunocleared in a solution containing 45 µl of a 50% slurry of either Protein A or Protein G Sepharose 4 Fast Flow (Amersham Biosciences, Piscataway, NJ) in Tris-EDTA (TE) buffer, pH 8, 2 µg salmon sperm DNA (Invitrogen), and 20 µl normal serum (Sigma) for 2 h at 4 C; use of protein A or protein G was determined based on which had stronger affinity for each particular antibody (based on supplier’s recommendation). Supernatants were collected and incubated overnight at 4 C with one of the following antibodies: 1 µg mouse monoclonal human ER{alpha} antibody (Ab-10; NeoMarkers/Lab Vision, Fremont, CA), 2 µg mouse monoclonal human HIF-1{alpha} antibody (BD Biosciences, Palo Alto, CA), 5 µg mouse monoclonal human HIF-1ß antibody (BD Biosciences), 5 µg anti-p300 (N-15) rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 4 µg rabbit polyclonal Sp1 (H-225 or PEP 2) antibody (no. sc-14027 or sc-59; Santa Cruz Biotechnology), and 5 µg rabbit polyclonal Sp3 (H-225) antibody (no. sc-13018; Santa Cruz Biotechnology). For the "no antibody" control, an equal volume of normal mouse or rabbit serum was substituted for the specific mouse or rabbit antibody. Protein A or protein G sepharose beads (45 µl of a 50% slurry in TE buffer) and salmon sperm DNA (2 µg) were then added and incubated for 1 h at 4 C. The beads were then washed sequentially with 1 ml each of TSE I, TSE II, and buffer III (31), and then 2 x 1 ml of TE buffer (pH 8.0); each wash was for 10 min each at 4 C. The protein-DNA complexes were then eluted by twice incubating beads in 100 µl of elution buffer (1% sodium dodecyl sulfate, 0.1 M NaHCO3) for 10 min at room temperature with vigorous mixing. To separate immunoprecipitated protein and DNA, the pooled eluates were incubated at 65 C overnight. The DNA was purified using the Qiaquick PCR Purification kit (QIAGEN). The final volume was 50 µl (10 mM Tris-HCl, pH 8.5).

The yield of target region DNA in each sample after ChIP was analyzed by both conventional and real-time PCR, as described previously. In both cases, 3 µl of each 50-µl sample was amplified. For real-time PCR, standard curves were generated by serially diluting an input chromatin sample. The following primers were used for ChIP PCR analysis (30 cycles at 60 C annealing temperature):

rat VEGF –944 to –611: forward 5'-TCTGCCAGACTCCACAGTG-3' and reverse 5'-TGCGTGTTTCTAACACCCAC-3' (GenBank accession no. U22373)

rat VEGF –661 to –384: forward 5'-GTTTCCGAGGTCAAACAAGC-3' and reverse 5'-CACACTATACCCAGACACAC-3' (GenBank accession no. U22373)

rat VEGF –403 to –124: forward 5'-GTGTGTCTGGGTATAGTGTG-3' and reverse 5'-GCCACTACTGCGAAATAGAAA-3' (GenBank accession no. U22373)

rat VEGF –173 to +114: forward 5'-CAGGCTATGGACCCTGGTAA-3' and reverse 5'-ATAGTCTGCCTTGTCGCTGC-3' (GenBank accession no. U22373)

rat VEGF +666 to +928: forward 5'-TGAGTCAAGAGGACAGAGAG-3'and reverse 5'-ATTACCAGGCCTCTTCTTCC-3' (GenBank accession no. U22372)

rat CKB –678 to –319: forward 5'-GGAAAGAACCTGGGGATTTG-3'and reverse 5'-GTTAGCACTTGAGGTTCCTG-3' (GenBank accession no. M18668)

human pS2 –436 to +19: forward 5'-GGCCATCTCTCACTATGAATC-3'and reverse 5'-GGCAGGCTCTGTTTGCTTAAA-3' (GenBank accession no. X05030)

Western Blot Analysis
Rat uterine tissue was homogenized on ice in 200 µl radioimmunoprecipitation buffer (as described above) using a Tissue-Tearor rotor-stator homogenizer (Biospec Products) at power setting 1.5. The homogenate was then centrifuged at 3000 rpm for 30 min at 4 C, and the supernatant was collected, aliquoted, and stored at –80 C. The protein concentration was determined using the BCA Protein Assay (Pierce Chemical Co., Rockford, IL). Protein samples (20–40 µg depending on antibody used) were loaded onto either a 7.5% (for HIF-1{alpha}) or 10% (for HIF-1ß) SDS-PAGE gel and transferred overnight onto polyvinylidene fluoride membrane. Membranes were then blocked with 5% nonfat dry milk/1x TTBS (1x Tris-buffered saline with 0.1% Tween 20) for 1 h before being incubated for 2.5 h at room temperature with mouse monoclonal antibodies to either HIF-1{alpha} [no. 610958 (BD Biosciences) at 1:250; or NB100–105 (Novus Biologicals, Littleton, CO) at 1:10,000] or HIF-1ß (no. 611078, BD Biosciences at 1:1,000). After three 5-min washes in 1x TTBS, the membranes were incubated at room temperature for 30 min with 1:2000 goat antimouse IgG horseradish peroxidase-conjugated antibody (Upstate, Charlottesville, VA). The membranes were then washed three times for 5 min in 1x TTBS and two times for 5 min in 1x Tris-buffered saline at room temperature. Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life and Analytical Sciences, Boston, MA) was used for visualization of protein bands, according to the manufacturer’s instructions.

Statistical Analysis
Statistical analyses were done using factorial ANOVA and appropriate post hoc tests (StatView Version 4.5, Abacus Concepts, Berkeley, CA).


    FOOTNOTES
 
This work was supported by National Institutes of Health (NIH) Grant CA45055 and Cooperative Agreement U54 HD36207 (as part of the Specialized Cooperative Centers Program in Reproduction Research); a grant from the Women’s Health Research Group, University of Maryland, Baltimore, and NIH Institutional Training Grant HD07170 (to A.A.K); and a Pioneer Award from the School of Medicine (to R.D.K.).

First Published Online March 17, 2005

Abbreviations: ChIP, Chromatin immunoprecipitation; CKB, creatine kinase B; E2, 17ß-estradiol; ER, estrogen receptor {alpha}; ERE, estrogen response element; HIF-1, hypoxia-inducible factor 1; HRE, hypoxia response element; iNOS, inducible nitric oxide synthase; PI3K, phosphatidylinositol 3-kinase; RT, reverse transcription; TE, Tris-EDTA; UTR, untranslated region; VEGF, vascular endothelial growth factor.

Received for publication September 29, 2004. Accepted for publication March 8, 2005.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Ferrara N 1999 Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527–543[CrossRef][Medline]
  2. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22[Abstract/Free Full Text]
  3. Rockwell LC, Pillai S, Olson CE, Koos RD 2002 Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents. Biol Reprod 67:1804–1810[Abstract/Free Full Text]
  4. Koos RD, Rockwell LC 2005 The microvasculature of the endometrium. In: Shepro D, ed. Microvascular research: biology and pathology. San Diego: Academic Press/Elsevier; 557–564
  5. Cullinan-Bove K, Koos RD 1993 Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133:829–837[Abstract]
  6. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL, Makela S 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56:3954–3960[Abstract]
  7. Hyder SM, Stancel GM 2000 Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histol Histopathol 15:325–334[Medline]
  8. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN 2000 Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors {alpha} and ß. Proc Natl Acad Sci USA 97:10972–10977[Abstract/Free Full Text]
  9. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T 1994 Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 269:16433–16442[Abstract/Free Full Text]
  10. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ER{alpha} and ERß at AP1 sites. Science 277:1508–1510[Abstract/Free Full Text]
  11. Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905–2919[Abstract/Free Full Text]
  12. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S 2000 Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor {alpha} and Sp3 proteins. J Biol Chem 275:22769–22779[Abstract/Free Full Text]
  13. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, Safe S 2004 Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor {alpha} and SP proteins. Oncogene 23:1052–1063[CrossRef][Medline]
  14. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL 1996 Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613[Abstract]
  15. Semenza GL 2003 Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732[CrossRef][Medline]
  16. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D 2001 HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15:2445–2453[Abstract/Free Full Text]
  17. Wiener CM, Booth G, Semenza GL 1996 In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225:485–488[CrossRef][Medline]
  18. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin Jr WG 2001 HIF{alpha} targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468[Abstract/Free Full Text]
  19. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ 2001 Targeting of HIF-{alpha} to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472[Abstract/Free Full Text]
  20. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B 1998 Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1{alpha}/ARNT. EMBO J 17:5085–5094[Abstract/Free Full Text]
  21. Richard DE, Berra E, Pouyssegur J 2000 Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1{alpha} in vascular smooth muscle cells. J Biol Chem 275:26765–26771[Abstract/Free Full Text]
  22. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R 2001 Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res 89:47–54[Abstract/Free Full Text]
  23. Spinella F, Rosano L, Di Castro, V, Natali PG, Bagnato A 2002 Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1{alpha} in ovarian carcinoma cells. J Biol Chem 277:27850–27855[Abstract/Free Full Text]
  24. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL 2002 Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205–38211[Abstract/Free Full Text]
  25. Fukuda R, Kelly B, Semenza GL 2003 Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63:2330–2334[Abstract/Free Full Text]
  26. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW 2003 Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9:2416–2425[Abstract/Free Full Text]
  27. Qian D, Lin HY, Wang HM, Zhang X, Liu DL, Li QL, Zhu C 2004 Normoxic induction of the hypoxic-inducible factor-1{alpha} by interleukin-1ß involves the extracellular signal-regulated kinase 1/2 pathway in normal human cytotrophoblast cells. Biol Reprod 70:1822–1827[Abstract/Free Full Text]
  28. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K 2004 Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 279:2550–2558[Abstract/Free Full Text]
  29. Gao N, Nester RA, Sarkar MA 2004 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1{alpha} and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol 196:124–135[CrossRef][Medline]
  30. Kuo MH, Allis CD 1999 In vivo cross-linking and immunoprecipitation for studying dynamic protein:DNA associations in a chromatin environment. Methods 19:425–433[CrossRef][Medline]
  31. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843–852[CrossRef][Medline]
  32. Wang F, Samudio I, Safe S 2001 Transcriptional activation of rat creatine kinase B by 17ß-estradiol in MCF-7 cells involves an estrogen responsive element and GC-rich sites. J Cell Biochem 84:156–172[CrossRef][Medline]
  33. Oh SY, Park SK, Kim JW, Ahn YH, Park SW, Kim KS 2003 Acetyl-CoA carboxylase ß gene is regulated by sterol regulatory element-binding protein-1 in liver. J Biol Chem 278:28410–28417[Abstract/Free Full Text]
  34. Woelfle J, Chia DJ, Rotwein P 2003 Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem 278:51261–51266[Abstract/Free Full Text]
  35. Pentecost BT, Mattheiss L, Dickerman HW, Kumar SA 1990 Estrogen regulation of creatine kinase-B in the rat uterus. Mol Endocrinol 4:1000–1010[Abstract]
  36. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G 1997 Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15:669–676[CrossRef][Medline]
  37. Gille J, Swerlick RA, Caughman SW 1997 Transforming growth factor-{alpha}-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 16:750–759[Abstract/Free Full Text]
  38. Milanini J, Vinals F, Pouyssegur J, Pages G 1998 p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273:18165–18172[Abstract/Free Full Text]
  39. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M 1996 Induction of vascular endothelial growth factor by tumor necrosis factor {alpha} in human glioma cells. Possible roles of SP-1. J Biol Chem 271:28220–28228[Abstract/Free Full Text]
  40. Salimath B, Marme D, Finkenzeller G 2000 Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 19:3470–3476[CrossRef][Medline]
  41. Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K 2001 Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20:3751–3756[CrossRef][Medline]
  42. Levy AP, Levy NS, Wegner S, Goldberg MA 1995 Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270:13333–13340[Abstract/Free Full Text]
  43. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM 1996 An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93:12969–12973[Abstract/Free Full Text]
  44. Ebert BL, Bunn HF 1998 Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol 18:4089–4096[Abstract/Free Full Text]
  45. Semenza G 2002 Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993–998[CrossRef][Medline]
  46. Page EL, Robitaille GA, Pouyssegur J, Richard DE 2002 Induction of hypoxia-inducible factor-1{alpha} by transcriptional and translational mechanisms. J Biol Chem 277:48403–48409[Abstract/Free Full Text]
  47. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C 2001 Synergistic cooperation between hypoxia and transforming growth factor-ß pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276:38527–38535[Abstract/Free Full Text]
  48. Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur J 2000 Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 60:1171–1178[CrossRef][Medline]
  49. Hyder SM, Murthy L, Stancel GM 1998 Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392–395[Abstract]
  50. Bogin L, Degani H 2002 Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 62:1948–1951[Abstract/Free Full Text]
  51. Scott PA, Gleadle JM, Bicknell R, Harris AL 1998 Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer 75:706–712[CrossRef][Medline]
  52. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M 2002 Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors {alpha} and ß. Cancer Res 62:4977–4984[Abstract/Free Full Text]
  53. Reisinger K, Kaufmann R, Gille J 2003 Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J Cell Sci 116:225–238[Abstract/Free Full Text]
  54. Safe S 2001 Transcriptional activation of genes by 17ß-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231–252[Medline]
  55. Khan S, Abdelrahim M, Samudio I, Safe S 2003 Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17ß-estradiol in breast cancer cells. Endocrinology 144:2325–2335[Abstract/Free Full Text]
  56. Cameron VA, Autelitano DJ, Evans JJ, Ellmers LJ, Espiner EA, Nicholls MG, Richards AM 2002 Adrenomedullin expression in rat uterus is correlated with plasma estradiol. Am J Physiol Endocrinol Metab 282:E139–E146
  57. Economos K, MacDonald PC, Casey ML 1992 Endothelin-1 gene expression and biosynthesis in human endometrial HEC1A cancer cells. Cancer Res 52:554–557[Abstract]
  58. Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, Okamura K 2002 Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 8:441–446[Abstract/Free Full Text]
  59. Giudice LC, Milkowski DA, Fielder PJ, Irwin JC 1991 Characterization of the steroid-dependence of insulin-like growth factor-binding protein-2 synthesis and mRNA expression in cultured human endometrial stromal cells. Hum Reprod 6:632–640[Abstract]
  60. Cameron IT, Campbell S 1998 Nitric oxide in the endometrium. Hum Reprod Update 4:565–569[Abstract/Free Full Text]
  61. Wenger RH 2002 Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16:1151–1162[Abstract/Free Full Text]
  62. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292–1300[Abstract]
  63. Endoh H, Sasaki H, Maruyama K, Takeyama K, Waga I, Shimizu T, Kato S, Kawashima H 1997 Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem Biophys Res Commun 235:99–102[CrossRef][Medline]
  64. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ 2001 Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor {alpha} (ER{alpha}) via interaction between ER{alpha} and PI3K. Cancer Res 61:5985–5991[Abstract/Free Full Text]
  65. Simoncini T, Fornari L, Mannella P, Varone G, Caruso A, Liao JK, Genazzani AR 2002 Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor {alpha} with phosphatidylinositol 3-OH kinase. Steroids 67:935–939[CrossRef][Medline]
  66. Farach-Carson MC, Davis PJ 2003 Steroid hormone interactions with target cells: cross talk between membrane and nuclear pathways. J Pharmacol Exp Ther 307:839–845[Abstract/Free Full Text]
  67. Xu Y, Traystman RJ, Hurn PD, Wang MM 2003 Neurite-localized estrogen receptor-{alpha} mediates rapid signaling by estrogen. J Neurosci Res 74:1–11[CrossRef][Medline]
  68. Marquez DC, Pietras RJ 2001 Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20:5420–5430[CrossRef][Medline]
  69. Milanini-Mongiat J, Pouyssegur J, Pages G 2002 Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277:20631–20639[Abstract/Free Full Text]
  70. Schafer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Hocker M 2003 Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 278:8190–8198[Abstract/Free Full Text]
  71. Clark JD, Mani SK 1994 Actions of ovarian steroid hormones. In: Knobil E, Neill JD, eds. The physiology of reproduction. New York: Raven Press; 1011–1062
  72. Kazi AK, Koos RD, Comparison of the effects of estrogen and relaxin on binding of estrogen receptors and coregulators to an estrogen-responsive gene promoter using chromatin immunoprecipitation. Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, 2003, p 328 (Abstract P2-86)
  73. Bermont L, Lamielle F, Lorchel F, Fauconnet S, Esumi H, Weisz A, Adessi GL 2001 Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab 86:363–368[Abstract/Free Full Text]
  74. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Harkonen PL 1999 Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149:29–40[CrossRef][Medline]
  75. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL 2001 HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1{alpha} (HIF-1{alpha}) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004[Abstract/Free Full Text]
  76. Navarro FJ, Mirkin S, Archer DF 2003 Effect of raloxifene, 17ß-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells. Fertil Steril 79:1409–1415[CrossRef][Medline]
  77. Kodama T, Shimizu N, Yoshikawa N, Makino Y, Ouchida R, Okamoto K, Hisada T, Nakamura H, Morimoto C, Tanaka H 2003 Role of the glucocorticoid receptor for regulation of hypoxia-dependent gene expression. J Biol Chem 278:33384–33391[Abstract/Free Full Text]
  78. Huang LE, Ho V, Arany Z, Krainc D, Galson D, Tendler D, Livingston DM, Bunn HF 1997 Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Kidney Int 51:548–552[Medline]
  79. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C 2002 Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-ß pathways. J Biol Chem 277:43799–43808[Abstract/Free Full Text]
  80. Miki N, Ikuta M, Matsui T 2004 Hypoxia-induced activation of the retinoic acid receptor-related orphan receptor {alpha}4 gene by an interaction between hypoxia-inducible factor-1 and Sp1. J Biol Chem 279:15025–15031[Abstract/Free Full Text]
  81. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I 2003 The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci USA 100:6517–6522[Abstract/Free Full Text]
  82. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D’Acquisto F, Addeo R, Makuuchi M, Esumi H 2000 Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95:189–197[Abstract/Free Full Text]
  83. Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M 2001 HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 52:49–53[CrossRef][Medline]
  84. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E 1993 Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 91:2235–2243[Medline]
  85. Karuri AR, Kumar AM, Mukhopadhyay D 1998 Differential expression and selective localization of vascular permeability factor/vascular endothelial growth factor in the rat uterus during the estrous cycle. J Endocrinol 159:489–499[Abstract/Free Full Text]
  86. Yi XJ, Jiang HY, Lee KK, O WS, Tang PL, Chow PH 1999 Expression of vascular endothelial growth factor (VEGF) and its receptors during embryonic implantation in the golden hamster (Mesocricetus auratus). Cell Tissue Res 296:339–349[CrossRef][Medline]
  87. Daikoku T, Matsumoto H, Gupta RA, Das SK, Gassmann M, DuBois RN, Dey SK 2003 Expression of hypoxia-inducible factors in the peri-implantation mouse uterus is regulated in a cell-specific and ovarian steroid hormone-dependent manner. Evidence for differential function of HIFs during early pregnancy. J Biol Chem 278:7683–7691[Abstract/Free Full Text]
  88. Zhang J, Salamonsen LA 2002 Expression of hypoxia-inducible factors in human endometrium and suppression of matrix metalloproteinases under hypoxic conditions do not support a major role for hypoxia in regulating tissue breakdown at menstruation. Hum Reprod 17:265–274[Abstract/Free Full Text]




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
19/8/2006    most recent
Author Manuscript (PDF)
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Request Copyright Permission
Google Scholar
Articles by Kazi, A. A.
Articles by Koos, R. D.
Articles citing this Article
PubMed
PubMed Citation
Articles by Kazi, A. A.
Articles by Koos, R. D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals